Matrix Metalloproteinase-dependent Activation of Latent Transforming Growth Factor-β Controls the Conversion of Osteoblasts into Osteocytes by Blocking Osteoblast Apoptosis*

  1. Niels T. Foged
  1. From the Nordic Bioscience A/S, Center for Clinical and Basic Research, Herlev/Ballerup, Herlev DK-2730, Denmark

Abstract

Upon termination of bone matrix synthesis, osteoblasts either undergo apoptosis or differentiate into osteocytes or bone lining cells. In this study, we investigated the role of matrix metalloproteinases (MMPs) and growth factors in the differentiation of osteoblasts into osteocytes and in osteoblast apoptosis. The mouse osteoblast cell line MC3T3-E1 and primary mouse calvarial osteoblasts were either grown on two-dimensional (2-D) collagen-coated surfaces, where they morphologically resemble flattened, cuboidal bone lining cells, or embedded in three-dimensional (3-D) collagen gels, where they resemble dendritic osteocytes constituting a network of cells. When MC3T3-E1 osteoblasts were grown in a 3-D matrix in the presence of an MMP inhibitor (GM6001), the cell number was dose-dependently reduced by approximately 50%, whereas no effect was observed on a 2-D substratum. In contrast, the murine mature osteocyte cell line, MLO-Y4, was unaffected by GM6001 under all culture conditions. According to TUNEL assay, the osteoblast apoptosis was increased 2.5-fold by 10 μm GM6001. To investigate the mechanism by which MMPs mediate the survival of osteoblasts, we examined the effect of GM6001 on MC3T3-E1 osteoblasts in the presence of extracellular matrix components and growth factors, including tenascin, fibronectin, laminin, collagenase-cleaved collagen, gelatin, parathyroid hormone, basic fibroblast growth factor, vascular epidermal growth factor, insulin-like growth factor, interleukin-1, and latent and active transforming growth factor-β (TGF-β). Only active TGF-β, but not latent TGF-β or other agents tested, restored cell number and apoptosis to control levels. Furthermore, we found that the membrane type MMP, MT1-MMP, which is produced by osteoblasts, could activate latent TGF-β and that antibodies neutralizing endogenous TGF-β led to a similar decrease in cell number as GM6001. Whereas inhibitors of other protease families did not induce osteoblast apoptosis, an inhibitor of the p44/42 mitogen-activated protein kinase showed the same but non-synergetic effect as GM6001. These findings suggest that MMP-activated TGF-β maintains osteoblast survival during trans-differentiation into osteocytes by a p44/42-dependent pathway.

  • Abbreviations:
    MMP
    matrix metalloproteinase
    ECM
    extracellular matrix
    2-D
    two-dimensional
    3-D
    three-dimensional
    αMEM
    minimal essential medium
    TGF-β
    transforming growth factor-β
    PTH
    parathyroid hormone
    DAPI
    4′,6-diamidine-2-phenylindole
    TUNEL
    terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling
    VEGF
    vascular epidermal growth factor
    MAPK
    mitogen-activated protein kinase
    MT1-MMP
    membrane type 1 MMP
    • Received July 18, 2002.
    • Revision received September 4, 2002.
    Table of Contents

    This Article

    1. The Journal of Biological Chemistry 277, 44061-44067.
    1. All Versions of this Article:
      1. M207205200v1
      2. 277/46/44061 (most recent)

    Article Usage Stats

    Submit your work to JBC.

    You'll be in good company.